Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:morphine_sulfate
|
| gptkbp:approvedBy |
1987
|
| gptkbp:ATCCode |
N02AA01
|
| gptkbp:brand |
gptkb:morphine
|
| gptkbp:compatibleWith |
as-needed pain relief
|
| gptkbp:contraindication |
respiratory depression
acute asthma paralytic ileus |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:duration |
8-12 hours
|
| gptkbp:eliminatedIn |
renal
|
| gptkbp:form |
gptkb:tablet
extended-release tablet |
| gptkbp:genericAvailable |
yes
|
| gptkbp:halfLife |
2-4 hours (morphine)
|
| https://www.w3.org/2000/01/rdf-schema#label |
MS Contin
|
| gptkbp:indication |
chronic pain
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Purdue_Pharma
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:riskFactor |
addiction
overdose abuse potential |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation drowsiness respiratory depression |
| gptkbp:usedFor |
moderate to severe pain
|
| gptkbp:bfsParent |
gptkb:Morphine
gptkb:Purdue_Pharma |
| gptkbp:bfsLayer |
6
|